greeksoup/ stocks
Stocks / United States / INCY · Services-Commercial Physical & Biological Research · Nasdaq

Incyte Corp. (INCY)

Compare with another name

Incyte Corp. (INCY) reported revenue of $1.3 billion for Q1 FY2026, the quarter ended 31 March 2026, up 20.9% on the same quarter a year earlier. Net income was $303 million, up 91.7% on the year, and diluted earnings per share $1.47. The figures are the company's own, from the 10-Q it filed with the SEC on 28 April 2026.

Revenue$1.3 billionup 20.9%
Net income$303 millionup 91.7%
Diluted EPS$1.47
QuarterQ1 FY2026ended 31 March 2026

Ratios

From the filings

ROE25.5%
ROCE28.6%
Operating margin30.0%
Net margin26.7%
FCF marginn/a
Interest cover689.26
Debt to equity9.91
Cash conversion1.06
Share count, 1 year3.2%
Sales CAGR, 3 years14.8%
Profit CAGR, 3 years55.7%
EPS, TTM$7.08

At the close of 21 September 2026

Price$124.65
Market cap$24.9 billion
Stock P/E17.61
Price to book4.43
EV / EBITDA12.58
Dividend yieldn/a
Market cap / sales4.65
52-week high$129.93
52-week low$81.66
Price, 1 year44.1%
Price CAGR, 3 years29.0%
Price CAGR, 5 years12.4%

Every figure is arithmetic on the filed lines (hover a name for the formula); the priced ones use the latest daily close, CBOE delayed quotes, daily history, by CBOE, for splits. Debt to equity here stands on long-term debt as Incyte Corp. files it, at the balance sheet of 31 December 2018, the latest that carries it, with lease liabilities counted separately and never inside it. Nothing here is a valuation or a view.

Price, 17 September 2021 to 21 September 2026

Daily closes from CBOE delayed quotes, daily history, by CBOE, for splits; the last is 21 September 2026. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Drawn in your browser; the range and overlay you pick are remembered here only.

The public record on INCY

Filings22 in twelve months: 14 current reports (8-K), about 5 other events; 4 results of operations; 4 officer or director change; 1 shareholder vote
Planned insider sales49 Form 144 notices in twelve months, $107.7 million; latest 15 September 2026
Options tapeput/call 3.04 by open interest on 23 September 2026; the straddle prices a 6.8% move to 16 October 2026
Holders9 of the followed funds hold it; largest Dodge & Cox; 5 Schedule 13D or 13G filings in twelve months
Insider trading28 sales and 0 purchases on Form 4 in twelve months
Congress0 House trades disclosed in six months
Short interest9.4 million shares short, 7.69 days to cover at 31 August 2026
Documentsthe 10-K, the 10-Qs, the proxy and 4 earnings press releases, each linked

Quarterly results, the last 12 quarters

Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026
Revenue9559191,0138811,0441,1381,1791,0531,2161,3661,5071,273
Cost of revenue68.360.169.861.076.686.088.573.278.899.0121105
Gross profit8868599448209671,0521,0909801,1371,2671,3861,168
Gross margin93%93%93%93%93%92%92%93%94%93%92%92%
R&D4013764444291,138573466437495507611516
SG&A284268294300306309327326331329390328
Operating income19421518791.9-478146302205530444336301
Operating margin20%23%18%10%-46%13%26%19%44%32%22%24%
Interest expense0.70.60.80.40.70.80.40.70.60.60.60.6
Pre-tax income278234271236-390157314234558482390344
Tax rate27%27%26%28%n/a32%36%32%27%12%23%12%
Net income204171201170-445106201158405424299303
Net margin21%19%20%19%-43%9%17%15%33%31%20%24%
Diluted EPS$0.90$0.76$0.89$0.75-$2.04$0.54$0.90$0.80$2.04$2.11$1.46$1.47
Operating cash flow307148148219-57631138126644.7559543369
Buybacksn/a0.0n/an/an/a0.1n/an/an/a0.0n/an/a
Shares outstanding223m224m224m225m192m193m193m194m194m196m198m200m
Filing10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Profit and loss, 12 fiscal years and the trailing twelve months

FY2014 FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023 FY2024FY2025TTM
Revenue5117541,1061,5361,8822,1592,6672,9863,3953,6964,2415,1415,361
Cost of revenue3.027.058.279.594.1114131151207255312372403
Gross profit5087271,0481,4571,7882,0452,5352,8353,1883,4413,9294,7694,958
Gross margin99.4%96.4%94.7%94.8%95.0%94.7%95.1%94.9%93.9%93.1%92.6%92.8%92.5%
Research and development3484805821,3261,1981,1542,2161,4581,5861,6282,6072,0502,129
Selling, general and administrative1661973033664344695177401,0021,1561,2421,3761,379
Operating income-4.850.7145-244129402-26458657962161.41,5151,611
Operating margin-0.9%6.7%13.1%-15.9%6.9%18.6%-9.9%19.6%17.1%16.8%1.4%29.5%30.0%
Interest expense46.845.638.76.91.51.92.21.92.72.62.32.42.3
Pre-tax income-48.57.6107-312115487-2325705298343171,6641,774
Income tax-0.11.03.20.95.939.963.5-378188237284378342
Effective tax raten/a13.6%3.0%n/a5.1%8.2%n/a-66.3%35.6%28.4%89.7%22.7%19.3%
Net income-48.56.5104-313109447-29694934159832.61,2871,432
Net margin-9.5%0.9%9.4%-20.4%5.8%20.7%-11.1%31.8%10.0%16.2%0.8%25.0%26.7%
Diluted EPS-$0.29$0.03$0.54-$1.53$0.51$2.05-$1.36$4.27$1.52$2.65$0.15$6.41$7.08
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

Income statement lines from each year's 10-K, the year linked to its filing; TTM is the sum of the last four quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Cash flow and capital returned

FY2014 FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023 FY2024FY2025TTM
Operating cash flown/a89.4305-93.0336711-1257499704963351,4131,517
Capital expenditure27.926.012011173.578.118718177.8n/an/an/an/a
Free cash flown/a63.4184-204263633-312568892n/an/an/an/a
Free cash flow marginn/a8.4%16.7%-13.3%14.0%29.3%-11.7%19.0%26.3%n/an/an/an/a
Depreciation and amortisation41.444.958.452.255.054.551.857.867.982.789.293.394.7
Share-based compensation62.269.996.2133148167178183188216266249252
Buybacksn/an/an/an/an/an/an/an/a0.00.02,0050.0n/a
Diluted shares, weighted168m187m194m205m216m218m218m222m224m226m211m201m207m
Shares outstanding at period end171m187m189m211m213m216m219m221m223m224m193m198m200m
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

Buybacks and dividends are the cash paid in the year, from the cash flow statement; the dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet at year end

FY2014 FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023 FY2024FY2025TTM
Total assets7961,0071,6392,3032,6463,4273,5614,9335,8416,7825,4446,9587,339
Cash and equivalents4525216529001,1641,8331,5132,0572,9513,2131,6883,0983,461
Inventory0.41.84.16.57.011.416.427.942.063.058.9101116
Goodwilln/an/a156156156156156156156156156133133
Long-term debt84175075026.819,094n/an/an/an/an/an/an/an/a
Borrowings, as the company tags them59062065116.617.4n/an/an/an/an/an/an/an/a
Operating lease liabilitiesn/an/an/an/an/a11.914.215.614.114.316.814.5n/a
Finance lease liabilitiesn/an/an/an/an/a31.932.631.630.129.233.530.229.4
Shareholders' equity-81.61714191,6311,9262,5982,6113,7704,3705,1903,4485,1675,623
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

At the fiscal year end; the TTM column is the latest quarter end. A line the company does not tag under the usual name is left out.

Compounded growth

10 years5 years3 yearsTTM
Sales growth, compounded21.2%14.0%14.8%21.5%
Profit growth, compounded69.6%n/a55.7%6631.4%
Return on equity, average8.8%14.1%12.5%24.9%

Compounded growth is the latest fiscal year over the year that many years earlier, annualised; the TTM column is the last four quarters over the four before. Return on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Peers: Services-Commercial Physical & Biological Research

CompanyMarket capP/EROEOp. marginSales growth
TTM
Debt to equityDiv. yield
IQVIA Holdings Inc. IQV$45.0 billion33.5322.3%13.2%7.3%2.25n/a
Incyte Corp. INCY$24.9 billion17.6125.5%30.0%21.5%9.91n/a
Charles River Laboratories International, Inc. CRL$13.3 billionn/a-8.4%2.3%-0.7%0.92n/a

The names on this site in the same industry (the SEC's SIC description), by market capitalisation. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close.

Filings

FilingPeriodFiledWhere
10-Q30 June 202628 July 2026EDGAR
10-Q31 March 202628 April 2026EDGAR
10-K31 December 202510 February 2026EDGAR
10-Q30 September 202528 October 2025EDGAR
10-Q30 June 202529 July 2025EDGAR
10-Q31 March 202529 April 2025EDGAR
10-K31 December 202410 February 2025EDGAR
10-Q30 September 202429 October 2024EDGAR
10-Q30 June 202430 July 2024EDGAR
10-Q31 March 202430 April 2024EDGAR

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install